Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068234 | 1.00 | BLM (0.55) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL4375767 | 0.98 | BLM (0.52) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL21417696 | 0.84 | BLM (0.57) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL19368040 | 0.84 | SLC1A3 (0.38) | BLMGAAHTTCA1ALDH1A1 | |
| SCHEMBL7071560 | 0.84 | SLC1A3 (0.38) | BLMGAAHTTCA1ALDH1A1 | |
| SCHEMBL20994108 | 0.83 | BLM (0.55) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL2912386 | 0.82 | BLM (0.43) | BLMLMNAMEN1ALOX15KMT2A | |
| SCHEMBL26770999 | 0.81 | ACE2 (0.37) | BLMLMNAALOX15KMT2AACE2 | |
| Phytanic Acid SCHEMBL3819827 | 0.80 | BLM (0.63) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL12713322 | 0.80 | BLM (0.57) | BLMLMNAPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503483-B2 | Gemcitabine amphiphile prodrugs | NanoMed Holdings Pty Ltd (AU) | 2025-12-23 | — | — | US | claimed |
| US-20210238214-A1 | GEMCITABINE AMPHIPHILE PRODRUGS | NanoMed Holdings Pty Ltd (AU) | 2021-08-05 | — | — | US | claimed |
| EP-3784681-A1 | GEMCITABINE AMPHIPHILE PRODRUGS | NanoMed Holdings Pty Ltd (AU) | 2021-03-03 | — | — | EP | claimed |
| US-7179842-B2 | Method of treating non-insulin dependent diabetes mellitus with phytanic acid derivatives | DSM NUTRITIONAL PRODUCTS, INC. (US) | 2007-02-20 | — | — | US | claimed |
| US-20040138181-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | ROCHE VITAMINS INC. | 2004-07-15 | — | — | US | claimed |
| US-20020082298-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | F. HOFFMANN-LA ROCHE AG | 2002-06-27 | — | — | US | claimed |
| EP-1177789-A2 | Use of phytanic acid for the treatment of diabetes | Roche Vitamins AG (CH) | 2002-02-06 | — | — | EP | claimed |
| US-12503483-B2 | Gemcitabine amphiphile prodrugs | NanoMed Holdings Pty Ltd (AU) | 2025-12-23 | — | — | US | disclosed |
| US-20210238214-A1 | GEMCITABINE AMPHIPHILE PRODRUGS | NanoMed Holdings Pty Ltd (AU) | 2021-08-05 | — | — | US | disclosed |
| EP-3784681-A1 | GEMCITABINE AMPHIPHILE PRODRUGS | NanoMed Holdings Pty Ltd (AU) | 2021-03-03 | — | — | EP | disclosed |
| US-20140073703-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | OLOFSSON PETER (SE) | 2014-03-13 | — | — | US | disclosed |
| US-20110015278-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | OLOFSSON PETER | 2011-01-20 | — | — | US | disclosed |
| EP-2249819-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | Olofsson, Peter (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009113952-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | OLOFSSON PETER (SE) | 2009-09-17 | — | — | WO | disclosed |
| US-7179842-B2 | Method of treating non-insulin dependent diabetes mellitus with phytanic acid derivatives | DSM NUTRITIONAL PRODUCTS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-6784207-B2 | NON-INSULIN DEPENDENT DIABETES MELLITUS, SYNDROME X, HYPERLIPIDAEMIA, HYPERTENSION, HYPERINSULINAEMIA, HYPERCHOLESTERINAEMIA, HYPERTRIGLYCERINAEMIA, IMPAIRED GLUCOSE TOLERANCE AND RELATED OBESITY | ROCHE VITAMINS INC. | 2004-08-31 | — | — | US | disclosed |
| US-20040138181-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | ROCHE VITAMINS INC. | 2004-07-15 | — | — | US | disclosed |
| US-20020082298-A1 | Phytanic acid derivative compositions and method of treating and/or preventing diabetes mellitus | F. HOFFMANN-LA ROCHE AG | 2002-06-27 | — | — | US | disclosed |
| EP-1177789-A2 | Use of phytanic acid for the treatment of diabetes | Roche Vitamins AG (CH) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238214-A1 | GEMCITABINE AMPHIPHILE PRODRUGS | GBA1, GMNN, TYMP | BLM 399/4885LMNA 2993/4885PTPN1 2884/4885 |
| US-20140073703-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | SREBF2, PNLIP, APOL1 | BLM 4850/4885LMNA 753/4885PTPN1 733/4885 |
| US-12503483-B2 | Gemcitabine amphiphile prodrugs | GBA1, GMNN, TYMP | BLM 399/4885LMNA 2993/4885PTPN1 2884/4885 |
| US-20110015278-A1 | PHYTOL AS A CHOLESTEROL LOWERING AGENT | PNLIP, SREBF2, CETP | BLM 4854/4885LMNA 925/4885PTPN1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.